What Researchers Did
Researchers investigated how a specific hyperbaric oxygen therapy (HBOT) protocol, involving 90 minutes of discontinuous oxygen breathing at 0.25 MPa daily for 10 days, affected lung function in healthy volunteers and patients.
What They Found
Healthy volunteers showed no changes in lung function after a single HBOT session. However, patients who received the 10-day treatment experienced significant decreases in maximal expiratory flows (MEF) at 50% (-15%) and 25% (-33%) of forced vital capacity, though their overall forced vital capacity remained unchanged. These decrements were greater than those reported after continuous oxygen breathing of 210 min at 0.3 MPa (7% MEF50, 12% MEF25 decrement).
What This Means for Canadian Patients
This study indicates that repeated daily HBOT sessions using a specific discontinuous oxygen protocol can lead to measurable reductions in peripheral airway airflow, even without noticeable respiratory symptoms. Canadian patients undergoing similar HBOT regimens, particularly those with existing lung conditions, should be aware of these potential physiological changes.
Canadian Relevance
The study did not involve Canadian authors or institutions. While the study's category relates to carbon monoxide poisoning, a Health Canada-recognized indication for hyperbaric oxygen therapy, the research focused on the general physiological effects of HBOT protocols on lung function rather than treating a specific condition.
Study Limitations
The study's findings are based on a small sample size, and the patient group received additional medications which could have influenced the observed pulmonary function changes.